Eli Lilly and Company $LLY Shares Sold by Generali Investments Management Co LLC

Key Points

• Generali Investments Management Co LLC cut its Eli Lilly stake by 9.1%, selling 1,144 shares to finish the quarter with 11,423 shares worth $12.276 million (about 2.4% of its portfolio and LLY its 11th largest holding).
• Eli Lilly beat Q1 expectations with $7.54 EPS (vs. $7.48 est.) and $19.29 billion in revenue (up 42.6% YoY), and set FY‑2026 guidance of 33.50–35.00 EPS (consensus ~33.9).
• The company is boosting its pipeline via deals — including the acquisition of Ajax Therapeutics (up to $2.3bn) and a major AI drug‑discovery partnership (reported up to $2.25bn) — while facing mounting GLP‑1 competition that could weigh on near‑term growth and launch performance.

Generali Investments Management Co LLC reduced its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 9.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,423 shares of the company's stock after selling 1,144 shares during the period. Eli Lilly and Company comprises about 2.4% of Generali Investments Management Co LLC's portfolio, making the stock its 11th biggest holding. Generali Investments Management Co LLC's holdings in Eli Lilly and Company were worth $12,276,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Exencial Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 189.6% during the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock valued at $13,283,000 after purchasing an additional 11,396 shares in the last quarter. Rede Wealth LLC purchased a new position in Eli Lilly and Company during the third quarter valued at $487,000. Cidel Asset Management Inc. lifted its holdings in Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock valued at $20,392,000 after purchasing an additional 5,591 shares in the last quarter. Spire Wealth Management lifted its holdings in Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company's stock valued at $29,789,000 after purchasing an additional 592 shares in the last quarter. Finally, Coldstream Capital Management Inc. lifted its holdings in Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock valued at $32,365,000 after purchasing an additional 8,659 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $874.14 on Wednesday. The firm has a 50-day simple moving average of $952.17 and a 200-day simple moving average of $986.25. The stock has a market capitalization of $825.91 billion, a price-to-earnings ratio of 38.09, a price-to-earnings-growth ratio of 1.03 and a beta of 0.51. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts' consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company's quarterly revenue was up 42.6% compared to the same quarter last year. During the same period in the prior year, the business earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 33.9 earnings per share for the current fiscal year.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Acquisition — Lilly agreed to buy Ajax Therapeutics for up to $2.3 billion, adding a Type II JAK2 inhibitor for myelofibrosis and expanding its hematology/oncology pipeline. Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion
• Positive Sentiment: AI drug‑discovery partnership — Lilly struck a deal with AI startup Profluent (reported as up to $2.25 billion), signaling investment in AI-enabled discovery that could accelerate new programs and cost efficiency. Emeryville AI Upstart Snags $2.25 Billion Gene Editing Deal With Eli Lilly
• Positive Sentiment: Analyst support — Multiple analysts and outlets have reiterated bullish views (e.g., Barclays Overweight with a $1,350 target), supporting the narrative that Lilly’s deal cadence and diversified pipeline justify higher valuation. Analysts Reiterate Bullish Outlook on Eli Lilly and Company (LLY) Following Kelonia Acquisition
• Neutral Sentiment: Sector tone — Health‑care stocks broadly edged higher midday, providing modest tailwinds for large-cap pharma names including LLY. Sector Update: Health Care Stocks Edge Higher Late Afternoon
• Neutral Sentiment: Near‑term earnings focus — Analysts are parsing Q1 guidance and launch metrics ahead of results; market reaction may hinge on GLP‑1 trends and margins. Countdown to Lilly (LLY) Q1 Earnings: Wall Street Forecasts for Key Metrics
• Negative Sentiment: GLP‑1 competitive pressure — Data and prescription tracking show Novo Nordisk’s oral Wegovy gaining share vs. Lilly’s oral competitor, raising concerns about Foundayo adoption and near‑term revenue growth. GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival
• Negative Sentiment: New competitor data — A late‑stage obesity trial from Boehringer/Ingelheim showed meaningful weight loss, intensifying competition in the obesity space where Lilly has been a market leader. Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
• Negative Sentiment: Short‑term pullback/volatility — Shares pulled back with the broader market ahead of earnings as investors weigh pricing pressure, rising costs and softer launch datapoints. Pharmaceutical Stock Pulling Back Before Earnings

Analyst Upgrades and Downgrades

Several research firms have issued reports on LLY. Guggenheim increased their price objective on shares of Eli Lilly and Company from $1,163.00 to $1,183.00 and gave the company a "buy" rating in a report on Tuesday, April 21st. Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. UBS Group reaffirmed a "buy" rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Leerink Partners decreased their price objective on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an "outperform" rating on the stock in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $1,285.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $1,216.52.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.